News and Insights

Managing Globally and Locally

Optimizing Global Launch Sequencing

Traditionally, launch sequencing has been guided by market size, eligible patient population, and the likelihood of securing market access and adoption. While these criteria are still important, they’re no longer sufficient. Growing budget constraints, more stringent evidence requirements, and the rise of external reference pricing and transparency are forcing pharma…

Transatlantic Perspectives on the Future of Pharma

For years, lawmakers have targeted the pharmaceutical industry, blaming it for the high cost of healthcare – its role in the management of Covid-19 notwithstanding.  Despite recent breakthroughs to rid the world of its worst scourges, both the U.S. and EU appear to regard pharma as the single worst actor…

Market Access Outlook for Canada

Pharmaceutical Technology

Canada remains the ninth largest pharmaceutical market in the world, close to Spain and the United Kingdom. Drug makers operating in Canada have benefited from high per capita spending on pharmaceuticals and rising procurement as a result of the country’s aging population. In 2014 alone, the country spent an estimated…

Market Access in China

BioPharm International

Many pharmaceutical manufacturers consider China as one of the most important strategic markets for future growth. It’s the second largest market in the world after the United States. More importantly, China currently accounts for less than 3% of global revenue for most major pharmaceutical companies, leaving significant opportunity for expansion…